Delivered $25.6 million in revenue representing 42% growth in Q1 2026; Achieved 84% gross margin in Q1 2026; Increased FY 2026 Revenue Guidance to $108-114 million, mid-point reflects 25% growth; ...
Q1 2026 earnings call: 42% revenue growth, margin expansion, Nodify Lung adoption and raised 2026 guidance to $108–$114M—read now.
Total test volumes grew 29% year over year due to increased adoption from both pulmonology and primary care, with test ...
Potency assay development uses DoE and QbD to improve accuracy, consistency, and regulatory readiness in biologics testing.
A fusion energy company has, for the first time, formally asked to plug into the American power grid. Commonwealth Fusion ...
Cobra's driver lineup has gone through three distinct identities in its last three product cycles, moving from the H.O.T.